The anti-CTLA-4 antibody ipilimumab was the first immune checkpoint inhibitor approved in 2011 by the U.S. Food and Drug Administration for the treatment of late-stage melanoma (133), paving the way for the further research of immune checkpoint blockade. The gene discussed is CTLA4; the disease is melanoma.